Scynexis (SCYX) Asset Writedowns and Impairment (2015 - 2016)

Scynexis (SCYX) posted Asset Writedowns and Impairment of $111000.0 for Q1 2016, down 91.78% on a QoQ basis from $1.3 million in Q2 2015.

Scynexis (SCYX) Asset Writedowns and Impairment (2015 - 2016) Analysis & Trends

Scynexis' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $111000.0 for Q1 2016.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $111000.0 in Q1 2016, while the trailing twelve-month figure through Dec 2016 was $111000.0 (down 91.78% YoY) and the FY2023 annual result came in at $14.6 million, changed N/A from the prior year.
Asset Writedowns and Impairment was $111000.0 for Q1 2016 at Scynexis, down from $1.3 million in the prior quarter.
Across five years, Asset Writedowns and Impairment topped out at $1.3 million in Q2 2015 and bottomed at $111000.0 in Q1 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Scynexis	21.55 Mn	-15.20 Mn	-

Download Data